arrow
D

Dean F. Bajorin

Memorial Sloan Kettering Cancer Center
H指数:98
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FINAL RESULTS OF A PHASE II TRIAL OF BACILLUS CALMETTE-GUÉRIN (BCG) AND INTRAVESICAL GEMCITABINE FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NCT04179162)

BCG(卡介苗)和膀胱内注射吉西他滨治疗BCG暴露的高级别非肌层浸润性膀胱癌的II期临床试验最终结果(NCT04179162)

2026-05-010
PRE
CLINICAL, RADIOGRAPHIC, AND GENOMIC PREDICTORS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR HIGH-RISK LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA

高风险局限性上尿路尿路上皮癌对新辅助化疗反应的临床、放射影像学和基因组预测因子

2026-05-010
PRE
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort

高危局限性上尿路尿路上皮癌的新辅助化疗:来自一项II期临床试验和扩展队列的最终长期结果

2025-09-250
PREAI
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial

辅助性纳武利尤单抗在肌肉浸润性尿路上皮癌中的应用:随机III期CheckMate 274试验的探索性生物标志物分析

2025-08-070
PRE
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma☆

接受过恩普替尼韦汀治疗后的转移性尿路上皮癌患者中,沙西妥珠单抗戈维他胺的实时临床疗效☆

2025-06-010
OA
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

临床结局、基因组异质性及不同组织学亚型的尿路上皮癌的治疗考量

2025-04-260
PRE
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

2024-12-010
PRE
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications
2024-10-011
PRE
Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

接受恩沃利单抗(EV)单药治疗且未出现疾病进展的转移性尿路上皮癌(mUC)患者的临床结局

2024-09-010
PRE
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

在接受第二线帕博利珠单抗治疗的尿路上皮癌患者中,先前化疗对疗效的影响:KEYNOTE-045 III期试验的探索性分析

2024-08-220
PREAI
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024)
2024-03-011
OA
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
2024-03-0112
OAAI
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights

膀胱癌的全基因组关联研究揭示了新的生物学和转化见解

2023-07-0124
PRE
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma
2023-05-0111
OA
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
2023-05-0114
OA
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary
2023-03-152
OA
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation (vol 13, 6575, 2022)
2022-12-231
OAAI